Dr Reddy’s Laboratories Ltd (DRL) has entered into a strategic
partnership with Oregan-based Galena Bio to develop and commercialise
the latter’s preventive breast cancer drug in India.
DRL will also
lead the development of NeuVax, that helps prevention of recurrence of
breast cancer in patients under remission, in gastric cancer and help
expand the scope of therapy by addressing a new patient population.
As
per the terms of the agreement, Galena will licence commercial rights
of Neu Vax to DRL for breast cancer. Neu Vax (nelipepimut-S) is an
immunodominant nonapeptide derived from the extracellular domain of the
HER2 protein, a well-established target for therapeutic intervention in
breast carcinoma.
Galena will receive development and sales milestones, as well as double-digit royalties on net sales.
The licensing and development terms are conditioned to an agreement on ancillary activities. Read more..
Source: Hindi News
No comments:
Post a Comment